To sum up, ACE2 expression identifies TNBC subtype and resistance to endocrine therapy in BC, but patients with high ACE2 expression tend to be sensitive to more therapeutic opportunities, including chemotherapy, anti-ERBB therapy, antiangiogenic therapy, and immunotherapy. Here, ACE2 is linked to breast cancer.